Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06493760 |
TitleA Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | Phase
Phase 2
|
Date Added 2024-07-10 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03600883 |
TitleA Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | Phase
Phase 1, Phase 2
|
Date Added 2018-07-26 |
Location
California, United States
Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Indiana, United States Maryland, United States Massachusetts, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Brazil Canada France Germany Greece Hungary Japan Korea, Republic of Portugal Romania Spain Switzerland |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Anti PD-1/L1, Midazolam, Sotorasib |
Tags
MSS/ MMRp
|
| NCT ID NCT06055439 |
TitleA Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Phase
Phase 1, Phase 2
|
Date Added 2023-09-26 |
Location
Georgia, United States
Illinois, United States Pennsylvania, United States Tennessee, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06011772 |
TitleA Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | Phase
Early Phase 1
|
Date Added 2023-08-25 |
Location
New York, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Suspended
|
Drugs
fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06412198 |
TitleA Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | Phase
Phase 1, Phase 2
|
Date Added 2024-05-14 |
Location
Massachusetts, United States
Texas, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Adagrasib, cemiplimab, cetuximab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05865535 |
TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia | Phase
Phase 1
|
Date Added 2023-05-19 |
Location
California, United States
Florida, United States Georgia, United States Nebraska, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06010901 |
TitleA Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. | Phase
Phase 1
|
Date Added 2023-08-25 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Anlotinib hydrochloride capsules, Penpulimab Injection, TQB2618 injection |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05973487 |
TitleA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | Phase
Phase 1
|
Date Added 2023-08-03 |
Location
Arizona, United States
California, United States Connecticut, United States Florida, United States Illinois, United States Kentucky, United States Michigan, United States Minnesota, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06856837 |
Title– IKF/AIO-QUINTIS – Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | Phase
Phase 2
|
Date Added 2025-03-04 |
Location
Austria
Germany |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
